Orthopaedic industry revenue reached $48.1 billion worldwide in 2016 and grew at 3.2%, ~$1.5 billion over 2015, according to our estimates, which will be published in the forthcoming ORTHOPAEDIC INDUSTRY ANNUAL REPORT®.
Overall, 2,811 orthopaedic 510(k) clearances occurred between 2012 and 2016; of those, 76% were granted to U.S. companies. The five countries with the most 510(k)s following the U.S. were France, the U.K., South Korea, Germany and Switzerland.
We were first introduced to Dr. Pracyk in 2013. At the time he was a neurosurgeon, institute medical director, strategic healthcare consultant and one of our authors. Now, he is Franchise Medical Director for DePuy Synthes Spine, providing clinical insight to colleagues across R&D, marketing, clinical affairs, regulatory affairs and business development.
Using a generic, one-dimensional model of a human, Monk identified reasons for several trends that may impact joint reconstruction product development today and in the future.
The joint reconstruction segment is a priority for the five leading orthopaedic companies: DePuy Synthes, Zimmer Biomet, Stryker, Smith & Nephew...and yes, even Medtronic.
